Abstract:Objectives: Lung adenocarcinoma (LUAD) is the most common newly diagnosed malignant tumor in older people. As older patients age, organ function decreases, leading to increased adverse reactions to treatment. The epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase tyrosine (ALK) tyrosine kinase inhibitors (TKIs) therapy are more effective and well-tolerated than chemotherapy, while the rate of genetic testing and subsequent targeted treatment among older patients remains relatively low, the clinical benefit limitation for those patients. This study aims to investigate the mutation characteristics of LUAD diver gene and its relationship with clinicopathological features in older LUAD. Materials and methods: A total of 275 patients were diagnosed as LUAD and were over sixty years old. We utilized next-generation sequencing technology to detect and analyze gene mutations in postoperative tissue specimens, including EGFR, KRAS, ALK, ROS1, RET, MET, BRAF, HER2, PIK3CA and NRAS . Results: A total of 90.18% (248/275) of older LUAD patients experienced genetic mutations. The EGFR (192, 69.82%) had the highest mutation rate among ten genes, followed by KRAS (21, 7.64%), MET (21, 7.64%), ERBB2 (15, 5.45%), RET (9, 3.27%), ALK (8, 2.91%), ROS1 (8, 2.91%), PIK3CA (6, 2.18%), BRAF (5, 1.82%) and NRAS (1, 0.36%). We also found thirty patients (15.63%) with EGFR mutations also having other gene mutations. The L858R mutation and exon19 deletion were the predominant EGFR mutations, accounting for 84.90% of EGFR -mutated patients. In addition, fifty-one kinds of EGFR mutations were detected, distributed in the protein tyrosine kinase catalytic domain (43, 84.31%), cysteine enriched domain (4, 7.84%), receptor binding domain (3, 5.88%), and EGFR transmembrane domain (1,1.96%). Ten cases of gene fusion mutation were detected. Two rare partner genes, PKHD1 (P60:R34) and STK39 (R33:S11), were detected by ROS1 gene fusion. RET gene fusion revealed a rare companion gene KCND2 (R11:K2). The EGFR mutations were more prevalent in female, non-smoking patients (p < 0.05), and the KRAS mutations were more common in male and smoking patients (p < 0.01). In addition, the BRAF mutations were more likely to occur in the right lung (p < 0.05). Conclusion: Older LUAD populations exhibit diverse genetic mutations, which may also exist simultaneously. Simultaneous detection of multiple genes by NGS can accelerate and enhance targeted treatment benefits for older LUAD patients, ultimately improving their quality of life.

Association Between Young Age and Genomic Alterations in Never-Smoker Patients with Non–small Cell Lung Cancer

Demographics, Risk Factors and Survival Analysis of Lung Cancer in Young Adults (&lt;30 Years) in China-A Retrospective Cohort Study

Sex- and Age-Associated Differences in Genomic Alterations among Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

Clinical Features and Gene Mutations of Lung Cancer Patients 30 Years of Age or Younger

EGFR, ALK, RET, KRAS and BRAF Alterations in Never-Smokers with Non-Small Cell Lung Cancer.

Frequent Genomic Alterations and Better Prognosis among Young Patients with Non-Small-cell Lung Cancer Aged 40 Years or Younger

Clinical Characteristics Associated with Metastatic Nsclc Harboring Alk Rearrangements in Chinese Patients.

Clinical Significance of Age at Diagnosis among Young Non-Small Cell Lung Cancer Patients under 40 Years Old: a Population-Based Study

Next-generation Sequencing Reveals Age-dependent Genetic Underpinnings in Lung adenocarcinoma

Genomic Characteristics of Driver Genes in Chinese Patients with Non‐small Cell Lung Cancer

Relationship between driver gene mutations and clinical pathological characteristics in older lung adenocarcinoma

Real-world comprehensive genomic and immune profiling reveals distinct age- and sex-based genomic and immune landscapes in tumors of patients with non-small cell lung cancer

[A Retrospective Analysis: Comparison of the Clinical Characteristics and Prognosis in Elderly and Young Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer.].

Spectrum of Oncogenic Driver Mutations in Lung Adenocarcinomas from East Asian Never Smokers

Frequency of Driver Mutations in Lung Adenocarcinoma from Female Never-Smokers Varies with Histologic Subtypes and Age at Diagnosis.

[Clinicopathological Features Associated with EGFR Gene Mutation in Non-Small Cell Lung Cancer Patients].

Driver gene alterations in NSCLC patients in southern China and their correlation with clinicopathologic characteristics

23P Genomic Profiling of Gene Aberrations in 323 Chinese NSCLC Patients

Analysis of the Molecular and Clinicopathologic Features of Surgically Resected Lung Adenocarcinoma in Patients under 40 Years Old.

Investigating the Genomic Alteration Improved the Clinical Outcome of Aged Patients with Lung Carcinoma

Targeted gene sequencing reveals disparate genomic mutations between young and older adults in renal cell carcinoma